Study S000528

A Trial to Compare the Injection Site Pain Experience of 0.25 mg Semaglutide B and Semaglutide D Administered sc

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT04143945
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 104
Start: 2019-10-28
Primary completion: 2020-01-04
Lead sponsor: Novo Nordisk A/S
Conditions: Healthy Volunteers Diabetes Mellitus, Type 2; Healthy Volunteers Overweight; Healthy Volunteers Obesity
Interventions: DRUG:Semaglutide (administered by DV3396 pen); DRUG:Semaglutide (administered by PDS290 pen)
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: REGISTRY:2019-003654-83; OTHER:U1111-1239-7955; NIH:2019

Registered primary outcomes

Intensity of Injection Site Pain [After 1 minute of each injection (Day 1)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0022123	Comparison of the injection-site experience of semaglutide in a single-dose and a multidose pen-injector. Snitker S, Diabetes, obesity & metabolism	2022	Commentary	PMID 35434913 DOI	cites ClinicalTrials.gov:NCT04143945; cites EudraCT:2019-003654-83; registry reference DERIVED:35434913